Covid-19 vaccines, treatment, equipment and manufacturing capacity in developing countries
This procedure examines how waiving certain intellectual property rights under the WTO TRIPS agreement affects the production and distribution of COVID-19 vaccines, treatments, and medical equipment. It aims to determine if removing these patent protections helps developing countries increase their manufacturing capacity to fight the pandemic.
The outcome primarily affects pharmaceutical companies, medical manufacturers, and healthcare systems in developing nations by potentially easing the legal restrictions on producing generic versions of COVID-19 medical products.
Documents
Covid-19 vaccines, treatment, equipment and manufacturing capacity in developing countries
motion · EN · 2026-05-03
Covid-19 vaccines, treatment, equipment and manufacturing capacity in developing countries
position · EN · 2026-05-03
Covid-19 vaccines, treatment, equipment and manufacturing capacity in developing countries
motion · EN · 2026-05-03
Covid-19 vaccines, treatment, equipment and manufacturing capacity in developing countries
motion · EN · 2026-05-03
Covid-19 vaccines, treatment, equipment and manufacturing capacity in developing countries
motion · EN · 2026-05-03
Covid-19 vaccines, treatment, equipment and manufacturing capacity in developing countries
motion · EN · 2026-05-03
Covid-19 vaccines, treatment, equipment and manufacturing capacity in developing countries
motion · EN · 2026-05-03